参苓白术颗粒联合吉非替尼对晚期非小细胞肺癌的治疗作用

参苓白术颗粒联合吉非替尼对晚期非小细胞肺癌的治疗作用

王永海1，邢建群2，寇丽春3

(1.怀来县医院内科，河北 怀来 075400；2.怀来县妇幼保健院，河北 怀来 075400；

3.怀来县沙城卫生院，河北 怀来 075400)

摘要：目的观察参苓白术颗粒联合吉非替尼对晚期非小细胞肺癌(NSCLC)的治疗效果。方法选取经病理组织学或细胞学确诊为NSCLC患者40例，随机分为治疗组及对照组。治疗组患者给予参苓白术颗粒口服，6 g/次，3次/d,吉非替尼250 mg/d口服；对照组仅给予吉非替尼250 mg/d口服。2组均连续治疗21 d为1个化疗周期，至少治疗3个周期，对比2组患者近期疗效、生活质量、中医症状改善及T细胞亚群变化。结果2组近期疗效比较无统计学意义(P>0.05)；治疗组治疗后生活质量KPS评分改善，中医证候临床疗效显著高于对照组(P<0.05)，治疗组治疗后CD4较治疗前升高(P<0.05)。结论参苓白术颗粒联合吉非替尼可显著改善晚期NSCLC患者生活质量，调节免疫功能。

关键词：参苓白术颗粒;吉非替尼;非小细胞肺癌;生活质量;免疫功能

DOI::10.13463/j.cnki.jlzyy.2015.07.013

中图分类号：R734.2文献标志码： A

文章编号：1003-5699(2015)07-0690-03

基金项目:张家口市科学技术研究与发展计划指令项目(11110013D)。

作者简介:王永海(1966-)，大学本科，副主任医师，主要从事肺癌的治疗研究。

收稿日期:(责任编辑：张晔2015-01-19)

Therapeutic effect of imatinib on advanced non-small cell lung

cancer Shenlingbaizhu granule combined with gefitinib

WANG Yonghai1,XING Jianqun2,KOU Lichun3

(1.Department of Internal Medicine,The Hospital of Hebei Huailai,Huailai 075400,Hebei Province,China;

2.Huailai Maternal and Child Health Care Hospital,Huailai 075400,Hebei Province,China;

3.Hebei Shacheng Hospital,Huailai 075400,Hebei Province,China)

Abstract:ObjectiveObservation of Shenling Baizhu granule combined with gefitinib in advanced non small cell lung cancer(NSCLC) treatment effect.MethodsSelect diagnosed by pathology or cytology of 40 cases of NSCLC patients,were randomly divided into treatment group and control group,the patients in the treatment group received oral Shenling Baizhu particles,6 g/3 times/d,gefitinib 250 mg/d orally;the control group only received gefitinib 250 mg/d orally;the two groups were treated for 21 d as 1 chemotherapy cycle,at least 3 cycles of treatment.A comparison of the short-term efficacy,quality of life,the two groups of patients with clinical symptoms improvement and the changes of T cell subset.ResultsNo significance between the two groups of curative effect in the near future (P>0.05);the treatment group after treatment,KPS score,quality of life to improve the clinical curative effect of TCM syndrome was significantly higher than that in control group (P<0.05).The treatment group CD4 after treatment than before treatment(P<0.05) increased.ConclusionLarge headed Atractylodes granule combined with gefitinib can significantly improve the life quality of patients with advanced NSCLC,regulate immune function.

Keywords:Shenlingbaishu ganute;gefitinib;NSCLC;quality of life;immune function

肺癌是我国高发的呼吸系统恶性疾病，其发病及病死率居恶性肿瘤之首[1-3]。肺癌按生物学特性不同，可分为非小细胞肺癌(NSCLC)及小细胞肺癌(SCLC)两大类,其中以NSCLC多见,约占肺癌发病的75%～80%[4]。NSCLC发病隐匿，确诊时多已进展至中晚期，失去了最佳手术治疗时机。多学科综合治疗可显著提高晚期NSCLC患者疗效,改善存活质量。其中以中医药在综合治疗中优势显著，通过扶正与祛邪相结合而达到治疗目的，可有效降低化疗的毒副反应,提高患者生活质量[5]。笔者……